X

Health & Biotech

Smiles takes ex-CEO, chair to court alleging illegal payments

Smiles Inclusive (ASX:SIL) is taking its former CEO and chairman to court over allegations of illegal payments and transactions. The…

Health: Paradigm in ‘no rush’ to partner with big pharma but analysts are alarmed

The chief of knee pain biotech Paradigm Biopharmaceuticals (ASX:PAR) says his company is in no rush to take the tried-and-true exit strategy…

Health: The cash keeps pouring in for Osprey, selling US$826k in devices last quarter

When your sole revenue source is a medical device costing $US350 each, you'd think cash would be difficult to come…

Australia and NZ will be drowning in milk by 2027 unless China laps it up

International demand -- particularly from China -- will bolster the Australian dairy formula industry as modest growth forecasts are predicted…

Koligo slashes IPO valuation by 33pc after institutions give it the side-eye

Stem-cell-but-not company Koligo Therapeutics (ASX:KOL) has had to make some radical changes to its IPO offer. The company has dropped…

Health: Great day for Paradigm as knee data drops and $78m cap raise opens

It's all happening in the offices of biotech Paradigm Biopharmaceuticals (ASX:PAR), which has today released the latest round of its Phase…

Dr Boreham’s Crucible: Does Osprey Medical’s GPO deal mean the cheque is in the US mail?

Having invented a device to reduce the usage of contrast dye used in x-rays, Osprey Medical (ASX: OSP) is heading…

The UK rolls out the welcome mat to MGC Pharma’s epilepsy treatment

Special Report: MCG Pharma can now legally import its cannabis-based CannEpil treatment into the UK, laying the foundation for wider…

Here are the ASX stocks chipper about Bill Shorten’s $2.3 billion cancer funding pledge

Aside from his plan to make Australia a world leader in lithium batteries -- which is causing the Liberal party…

Open wide and it won’t hurt as much: dental stocks and how they’re looking

Dental work is a little like a rising stock: you can put off buying it, but it’ll only get more…